Clinical Trial Update: Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial investigating precision, biomarker-guided combination therapies for multiple sclerosis, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Multiple Sclerosis | Phase 1, Phase 2 | Status: RECRUITING